Noninvasive strategies for breast cancer early detection

Papers of special note have been highlighted as: • of interest

References

• 1 Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98(19), 10869–10874 (2001). • It reports the subtype classification of breast carcinoma based on variation of gene-expression pattern.
  Medline CASGoogle Scholar
• 2 Curtis C, Shah SP, Chin SF et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486(7403), 346–352 (2012).
  Medline CASGoogle Scholar
• 3 The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490(7418), 61–70 (2012).
  MedlineGoogle Scholar
• 4 Zardavas D, Irrthum A, Swanton C, Piccart M. Clinical management of breast cancer heterogeneity. Nat. Rev. Clin. Oncol. 12(7), 381–394 (2015).
  Medline CASGoogle Scholar
• 5 Balduzzi S, Mantarro S, Guarneri V et al. Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst. Rev. 6, CD006242 (2014).
  MedlineGoogle Scholar
• 6 Fitzmaurice C, Dicker D, Pain A et al. The global burden of cancer. JAMA Oncol. 1(4), 505–527 (2013).
  Google Scholar
• 7 Goss PE, Strasser-Weippl K, Lee-Bychkovsky BL et al. Challenges to effective cancer control in China, India, and Russia. Lancet Oncol. 15(5), 489–538 (2014).
  MedlineGoogle Scholar
• 8 Etzioni R, Urban N, Ramsey S et al. The case for early detection. Nat. Rev. Cancer 3(4), 243–252 (2003).
  Medline CASGoogle Scholar
• 9 Cancer Statistics, SEER Stat Fact Sheets: Breast Cancer (2015). http://seer.cancer.gov/statfacts/html/breast.html.
  Google Scholar
• 10 Andre F, Mardis E, Salm M, Soria JC, Siu LL, Swanton C. Prioritizing targets for precision cancer medicine. Ann. Oncol. 25(12), 2295–2303 (2014).
  Medline CASGoogle Scholar
• 11 Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 339(6127), 1546–1558 (2013).
  Medline CASGoogle Scholar
• 12 Jamal-Hanjani M, Quezada SA, Larkin J, Swanton C. Translational implications of tumor heterogeneity. Clin. Cancer Res. 21(6), 1258–1266 (2015).
  Medline CASGoogle Scholar
• 13 Simpson PT, Reis-Filho JS, Gale T, Lakhani SR. Molecular evolution of breast cancer. J. Pathol. 205(2), 248–254 (2005).
  Medline CASGoogle Scholar
• 14 Umar A, Dunn BK, Greenwald P. Future directions in cancer prevention. Nat. Rev. Cancer 12(12), 835–848 (2012).
  Medline CASGoogle Scholar
• 15 Cimino-Mathews A, Foote JB, Emens LA. Immune targeting in breast cancer. Oncology 29(5), 375–85 (2015).
  MedlineGoogle Scholar
• 16 Matsumoto H, Koo SL, Dent R, Tan PH, Iqbal J. Role of inflammatory infiltrates in triple negative breast cancer. J. Clin. Pathol. 68(7), 506–510 (2015).
  Medline CASGoogle Scholar
• 17 Haick H, Broza YY, Mochalski P, Ruzsanyi V, Amann A. Assessment, origin, and implementation of breath volatile cancer markers. Chem. Soc. Rev. 43(5), 1423–1449 (2014).
  Medline CASGoogle Scholar
• 18 Alfaro JA, Sinha A, Kislinger T, Boutros PC. Onco-proteogenomics: cancer proteomics joins forces with genomics. Nat. Methods 11(11), 1107–1113 (2014).
  Medline CASGoogle Scholar
• 19 Mitchell P. Proteomics retrenches. Nat. Biotechnol. 28(7), 665–670 (2010).
  Medline CASGoogle Scholar
• 20 Nicholson JK, Lindon JC. Systems biology: metabonomics. Nature 455(7216), 1054–1056 (2008).
  Medline CASGoogle Scholar
• 21 Diamandis EP, van der Merwe DE. Plasma protein profiling by MS for cancer diagnosis: opportunities and limitations. Clin. Cancer Res. 11(3), 963–965 (2005).
  Medline CASGoogle Scholar
• 22 Chan DW, Beveridge RA, Muss H et al. Use of ruquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J. Clin. Oncol. 15(6), 2322–2328 (1997).
  Medline CASGoogle Scholar
• 23 Glasziou P, Houssami N. The evidence base for breast cancer screening. Prev. Med. 53(3), 100–102 (2011).
  MedlineGoogle Scholar
• 24 Coldman A, Phillips N, Wilson C et al. Pan-Canadian study of mammography screening and mortality from breast cancer. J. Natl Cancer Inst. 106(11), dju261 (2014).
  MedlineGoogle Scholar
• 25 Lauby-Secretan B, Scoccianti C, Loomis D et al. International Agency for Research on Cancer Handbook Working Group. Breast-cancer screening – viewpoint of the IARC Working Group. N. Engl. J. Med. 372(24), 2353–2358 (2015).
  Medline CASGoogle Scholar
• 26 Kuhl CK. Why do purely intraductal cancers enhance on breast MR images? Radiology 253(2), 281–283 (2009). • It enables to improve sensitivity of MRI, even in preinvasive carcinoma.
  MedlineGoogle Scholar
• 27 Sardanelli F, Podo F. Breast MR imaging in women at high-risk of breast cancer. Is something changing in early breast cancer detection? Eur. Radiol. 17(4), 873–887 (2007).
  MedlineGoogle Scholar
• 28 US Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 151(10), 716–726 (2009).
  MedlineGoogle Scholar
• 29 Kuhl CK, Schrading S, Leutner CC et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J. Clin. Oncol. 23(33), 8469–8476 (2005). • It is the first report focused on the relevance of MRI in early detection of breast carcinoma in high familial risk women.
  MedlineGoogle Scholar
• 30 Smith RA, Duffy SW, Gabe R, Tabar L, Yen AM, Chen TH. The randomized trials of breast cancer screening: what have we learned? Radiol. Clin. North. Am. 42(5), 793–806 (2004).
  MedlineGoogle Scholar
• 31 Ravert PK, Huffaker C. Breast cancer screening in women: an integrative literature review. J. Am. Acad. Nurse Pract. 22(12), 668–673 (2010).
  MedlineGoogle Scholar
• 32 Kaplan SS. Clinical utility of bilateral whole-breast US in the evaluation of women with dense breast tissue. Radiology 221(3), 641–649 (2001).
  Medline CASGoogle Scholar
• 33 Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J. Exp. Med. 133(2), 275–288 (1971). • It is the pioneer study on cancer angiogenesis and represents the biological basis of MRI interpretation.
  Medline CASGoogle Scholar
• 34 Sardanelli F, Podo F, Santoro F et al. High Breast Cancer Risk Italian 1 (HIBCRIT-1) Study. Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the High Breast Cancer Risk Italian 1 study): final results. Invest. Radiol. 46(2), 94–105 (2011). • It confirms the validity of MRI for diagnosis in mutation carrier women and endorses the role of MRI for dedicated programs of screening in women at high risk.
  MedlineGoogle Scholar
• 35 Kuhl CK, Weigel S, Schrading S et al. Prospective multicenter cohort study to refine management reccomendations for women at elevated familial risk of breast cancer: the EVA trial. J. Clin. Oncol. 28(9), 1450–1457 (2010).
  MedlineGoogle Scholar
• 36 Klijn JG. Early diagnosis of hereditary breast cancer by magnetic resonance imaging: what is realistic? J. Clin. Oncol. 28(9), 1441–1445 (2010).
  MedlineGoogle Scholar
• 37 Furman-Haran E, Schechtman E, Kelcz F, Kirshenbaum K, Degani H. Magnetic resonance imaging reveals functional diversity of the vasculature in benign and malignant breast lesions. Cancer 104(4), 708–718 (2005).
  MedlineGoogle Scholar
• 38 Moon M, Cornfeld D, Weinreb J. Dynamic contrast-enhanced breast MR imaging. Magn. Reson. Imaging Clin. N. Am. 17(2), 351–362 (2009).
  MedlineGoogle Scholar
• 39 Guo Y, Cai YQ, Cai ZL et al. Differentiation of clinically benign and malignant breast lesions using diffusion-weighted imaging. J. Magn. Reson. Imaging 16(2), 172–178 (2002).
  MedlineGoogle Scholar
• 40 Katz-Brull R, Lavin PT, Lenkinski RE. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J. Natl Cancer Inst. 94(16), 1197–1203 (2002).
  Medline CASGoogle Scholar
• 41 Leong KM, Lau P, Ramadan S. Utilisation of MR spectroscopy and diffusion weighted imaging in predicting and monitoring of breast cancer response to chemotherapy. J. Med. Imaging Radiat. Oncol. 59(3), 268–277 (2015).
  MedlineGoogle Scholar
• 42 Yamamoto S, Maki DD, Korn RL, Kuo MD Radiogenomic analysis of breast cancer using MRI: a preliminary study to define the landscape. AJR Am. J. Roentgenol. 199(3), 654–632 (2012).
  MedlineGoogle Scholar
• 43 Mazurowski MA, Zhang J, Grimm LJ, Yoon SC, Silber JI. Radiogenomic analysis of breast cancer: luminal B molecular subtype is associated with enhancement dynamics at MR imaging. Radiology 273(2), 365–372 (2014).
  MedlineGoogle Scholar
• 44 Yamamoto S, Han W, Kim Y et al. Breast cancer: radiogenomic biomarker reveals associations among dynamic contrast-enhanced MR imaging, long noncoding RNA, and metastasis. Radiology 275(2), 384–392 (2015).
  MedlineGoogle Scholar
• 45 Silva A, Bullock M, Calin G. The Clinical Relevance of Long noncoding RNAs in Cancer. Cancers 7(4), 2169–2182 (2015).
  Medline CASGoogle Scholar
• 46 Hu S, Loo JA, Wong DT. Human body fluid proteome analysis. Proteomics 6(23), 6326–6253 (2006).
  Medline CASGoogle Scholar
• 47 Beretov J, Wasinger VC, Graham PH, Millar EK, Kearsley JH, Li Y. Proteomics for breast cancer urine biomarkers. Adv. Clin. Chem. 63, 123–167 (2014).
  Medline CASGoogle Scholar
• 48 Bauça JM, Martínez-Morillo E, Diamandis EP. Peptidomics of urine and other biofluids for cancer diagnostics. Clin. Chem. 60(8), 1052–1061 (2014).
  Medline CASGoogle Scholar
• 49 Hu S, Loo JA, Wong DT. Human saliva proteome analysis and disease biomarker discovery. Expert. Rev. Proteomics. 4(4), 531–538 (2007).
  Medline CASGoogle Scholar
• 50 Streckfus C, Bigler L. The use of soluble, salivary c-erbB-2 for the detection and post-operative follow-up of breast cancer in women: the results of a five-year translational research study. Adv. Dent. Res. 18(1), 17–24 (2005).
  Medline CASGoogle Scholar
• 51 Cazzaniga M, Decensi A, Bonanni B, Luini A, Gentilini O. Biomarkers for risk assessment and prevention of breast cancer. Curr. Cancer Drug Targets. 9(4), 482–499 (2009).
  Medline CASGoogle Scholar
• 52 Hanash SM, Baik CS, Kallioniemi O. Emerging molecular biomarkers – blood-based strategies to detect and monitor cancer. Nat. Rev. Clin. Oncol. 8(3), 142–150 (2011).
  MedlineGoogle Scholar
• 53 Bidard FC, Peeters DJ, Fehm T et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 15(4), 406–414 (2014).
  MedlineGoogle Scholar
• 54 Koh CH, Bhoo-Pathy N, Ng KL et al. Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer. Br. J. Cancer 113(1), 150–158 (2015).
  Medline CASGoogle Scholar
• 55 Aarøe J, Lindahl T, Dumeaux V et al. Gene expression profiling of peripheral blood cells for early detection of breast cancer. Breast Cancer Res. 12(1), R7 (2010).
  MedlineGoogle Scholar
• 56 Best MG, Sol N, Kooi I et al. RNA-seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell 28(5), 666–676 (2015). • It proposes platelets as a tool for cancer diagnosis and classification.
  Medline CASGoogle Scholar
• 57 Vockley JG, Niederhuber JE. Diagnosis and treatment of cancer using genomics. BMJ 350, h1832 (2015).
  MedlineGoogle Scholar
• 58 Kittaneh M, Montero AJ, Glück S. Molecular profiling for breast cancer: a comprehensive review. Biomark. Cancer 5, 61–70 (2013).
  MedlineGoogle Scholar
• 59 Reuter JA, Spacek DV, Snyder MP. High-throughput sequencing technologies. Mol. Cell. 58(4), 586–597 (2015).
  Medline CASGoogle Scholar
• 60 Dawson SJ, Tsui DW, Murtaza M et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 368(13), 1199–1209 (2013).
  Medline CASGoogle Scholar
• 61 Olsson E, Winter C, George A et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol. Med. 7(8), 1034–1047 (2015).
  Medline CASGoogle Scholar
• 62 Warton K, Mahon KL, Samimi G Methylated circulating tumor DNA in blood: power in cancer prognosis and response. Endocr. Relat. Cancer. 23(3), R157–R171 (2016).
  Medline CASGoogle Scholar
• 63 Martínez-Galán J, Torres-Torres B, Núñez MI et al. ESR1 gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients. BMC Cancer 14, 59 (2014).
  MedlineGoogle Scholar
• 64 De Leeneer K, Claes K. Noncoding RNA molecules as potential biomarkers in breast cancer. Adv. Exp. Med. Biol. 867, 263–275 (2015).
  Medline CASGoogle Scholar
• 65 Redova M, Sana J, Slaby O. Circulating miRNAs as new blood-based biomarkers for solid cancers. Future Oncol. 9(3), 387–402 (2013).
  CASGoogle Scholar
• 66 Pimentel F, Bonilla P, Ravishankar YG et al. Circulating microRNAs as noninvasive cancer biomarkers in breast cancer. J. Lab. Autom. 20(5), 574–588 (2015).
  Medline CASGoogle Scholar
• 67 Zhang L, Song X, Wang X et al. Circulating DNA of HOTAIR in serum is a novel biomarker for breast cancer. Breast Cancer Res. Treat. 152(1), 199–208 (2015).
  Medline CASGoogle Scholar
• 68 Lacombe J, Mangé A, Solassol J. Use of autoantibodies to detect the onset of breast cancer. J. Immunol. Res. 2014, 574981 (2014).
  MedlineGoogle Scholar
• 69 Diaconu I, Cristea C, Hârceagă V, Marrazza G, Berindan-Neagoe I, Săndulescu R. Electrochemical immunosensors in breast and ovarian cancer. Clin. Chim. Acta 425, 128–138 (2013).
  Medline CASGoogle Scholar
• 70 Chen P, Chung MT, McHugh W et al. Multiplex serum cytokine immunoassay using nanoplasmonic biosensor microarrays. ACS Nano 9(4), 4173–4181 (2015).
  Medline CASGoogle Scholar
• 71 Seruga B, Zhang H, Bernstein LJ, Tannock IF. Cytokines and their relationship to the symptoms and outcome of cancer. Nat. Rev. Cancer 8(11), 887–899 (2008).
  Medline CASGoogle Scholar
• 72 Carlsson A, Wingren C, Kristensson M et al. Molecular serum portraits in patients with primary breast cancer predict the development of distant metastases. Proc. Natl Acad. Sci. USA 108(34), 14252–14257 (2011).
  Medline CASGoogle Scholar
• 73 Hong CC, Yao S, McCann SE et al. Pretreatment levels of circulating Th1 and Th2 cytokines, and their ratios, are associated with ER-negative and triple negative breast cancers. Breast Cancer Res. Treat. 139(2), 477–488 (2013).
  Medline CASGoogle Scholar
• 74 Crutchfield CA, Thomas SN, Sokoll LJ, Chan DW. Advances in MS-based clinical biomarker discovery. Clin. Proteom. 13, 1 (2016).
  MedlineGoogle Scholar
• 75 Zaidi AH, Gopalakrishnan V, Kasi PM et al. Evaluation of a 4-protein serum biomarker panel-biglycan, annexin-A6, myeloperoxidase, and protein S100-A9 (B-AMP)-for the detection of esophageal adenocarcinoma. Cancer 120(24), 3902–3913 (2014).
  Medline CASGoogle Scholar
• 76 Joshi S, Tiwari AK, Mondal B, Sharma A. Oncoproteomics. Clin. Chim. Acta 412(3–4), 217–226 (2011).
  Medline CASGoogle Scholar
• 77 Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat. Rev. Cancer 15(9), 540–555 (2015).
  Medline CASGoogle Scholar
• 78 Chen K, Gentry-Maharaj A, Burnell M et al. Microarray glycoprofiling of CA125 improves differential diagnosis of ovarian cancer. J. Proteome Res. 12(3), 1408–1418 (2013).
  Medline CASGoogle Scholar
• 79 Lam SW, Jimenez CR, Boven E. Breast cancer classification by proteomic technologies: current state of knowledge. Cancer Treat. Rev. 40(1), 129–138 (2014).
  Medline CASGoogle Scholar
• 80 Pitteri SJ, Amon LM, Busald Buson T et al. Detection of elevated plasma levels of epidermal growth factor receptor before breast cancer diagnosis among hormone therapy users. Cancer Res. 70(21), 8598–606 (2010).
  Medline CASGoogle Scholar
• 81 Villanueva J, Shaffer DR, Philip J et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest. 116(1), 271–284 (2006). • It proposes proteolytic degradative patterns of the serum peptidome as surrogate marker for detection and classification of cancer.
  Medline CASGoogle Scholar
• 82 Li Y, Li Y, Chen T et al. Circulating proteolytic products of carboxypeptidase N for early detection of breast cancer. Clin. Chem. 60(1), 233–242 (2014).
  Medline CASGoogle Scholar
• 83 Diamandis EP. Peptidomics for cancer diagnosis: present and future. J. Proteome Res. 5(9), 2079–2082 (2006).
  Medline CASGoogle Scholar
• 84 Orlandi R, De Bortoli M, Ciniselli CM et al. Hepcidin and ferritin blood level as noninvasive tools for predicting breast cancer. Ann. Oncol. 25(2), 352–357 (2014).
  Medline CASGoogle Scholar
• 85 Heiden MGV, Cantley LC, Thompson CB. Understanding the warburg effect: the metabolic requirements of cell proliferation. Science 324(5930), 1029–1033 (2009).
  MedlineGoogle Scholar
• 86 Wikoff WR, Hanash S, DeFelice B et al. Diacetylspermine is a novel prediagnostic serum biomarker for non-small-cell lung cancer and has additive performance with pro-surfactant protein B. J. Clin. Oncol. 33(33), 3880–3886 (2015).
  Medline CASGoogle Scholar
• 87 Sreekumar A, Poisson LM, Rajendiran TM et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457(7231), 910–914 (2009).
  Medline CASGoogle Scholar
• 88 Günther UL. Metabolomics biomarkers for breast cancer. Pathobiology 82(3–4), 153–165 (2015).
  Medline CASGoogle Scholar
• 89 McCulloch M, Jezierski T, Broffman M, Hubbard A, Turner K, Janecki T. Diagnostic accuracy of canine scent detection in early- and late-stage lung and breast cancers. Integrative Cancer Therapies 5(1), 30–39 (2006).
  MedlineGoogle Scholar
• 90 Ehmann R, Boedeker E, Friedrich U et al. Canine scent detection in the diagnosis of lung cancer: revisiting a puzzling phenomenon. Eur. Respir. J. 39(3), 669–676 (2012). • It provides strong evidence that breath indeed contains relevant biochemical information for cancer detection.
  Medline CASGoogle Scholar
• 91 Phillips M, Gleeson K, Hughes JMB et al. Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study. Lancet 353(9168), 1930–1933 (1999).
  Medline CASGoogle Scholar
• 92 Phillips M, Cataneo RN, Cummin ARC et al. Detection of lung cancer with volatile markers in the breath. Chest 123(6), 2115–2123 (2003).
  Medline CASGoogle Scholar
• 93 Phillips M, Cataneo RN, Ditkoff BA et al. Prediction of breast cancer using volatile biomarkers in the breath. Breast Cancer Res. Treat. 99(1), 19–21 (2006).
  Medline CASGoogle Scholar
• 94 Phillips M, Cataneo RN, Ditkoff BA et al. Volatile markers of breast cancer in the breath. Breast J. 9(3), 184–191 (2003).
  MedlineGoogle Scholar
• 95 Phillips M, Beatty JD, Cataneo RN et al. Rapid point-of-care breath test for biomarkers of breast cancer and abnormal mammograms. PLoS ONE 9(3), e90226 (2014).
  MedlineGoogle Scholar
• 96 Fang M, Ivanisevic J, Benton HP et al. Thermal degradation of small molecules: a global metabolomic investigation. Anal. Chem. 87(21), 10935–10941 (2015).
  Medline CASGoogle Scholar
• 97 Phillips M, Cataneo RN, Saunders C, Hope P, Schmitt P, Wai J. Volatile biomarkers in the breath of women with breast cancer. J. Breath. Res. 4(2), 026003 (2010).
  MedlineGoogle Scholar
• 98 Bajtarevic A, Ager C, Pienz M et al. Noninvasive detection of lung cancer by analysis of exhaled breath. BMC Cancer 9(1), 348 (2009).
  MedlineGoogle Scholar
• 99 Blake RS, Monks PS, Ellis AM. Proton-transfer reaction MS. Chem. Rev. 109(3), 861–896 (2009).
  Medline CASGoogle Scholar
• 100 Lindinger W, Hansel A, Jordan A. Proton-transfer-reaction MS (PTR-MS): on-line monitoring of volatile organic compounds at pptv levels. Chem. Soc. Rev. 27(5), 347–354 (1998).
  CASGoogle Scholar
• 101 Huang J, Kumar S, Abbassi-Ghadi N, Španěl P, Smith D, Hanna GB. Selected ion flow tube MS analysis of volatile metabolites in urine headspace for the profiling of gastro-esophageal cancer. Anal. Chem. 85(6), 3409–3416 (2013).
  Medline CASGoogle Scholar
• 102 Kumar S, Huang J, Cushnir JR, Španěl P, Smith D, Hanna GB. Selected ion flow tube-MS analysis of headspace vapor from gastric content for the diagnosis of gastro-esophageal cancer. Anal. Chem. 84(21), 9550–9557 (2012).
  Medline CASGoogle Scholar
• 103 Spaněl P, Smith D, Holland TA, Al Singary W, Elder JB. Analysis of formaldehyde in the headspace of urine from bladder and prostate cancer patients using selected ion flow tube MS. Rapid. Commun. Mass Spectrom. 13(14), 1354–1359 (1999).
  Medline CASGoogle Scholar
• 104 Sinues Martinez-Lozano P, Landoni E, Miceli R et al. Secondary electrospray ionization-MS and a novel statistical bioinformatic approach identifies a cancer-related profile in exhaled breath of breast cancer patients: a pilot study. J. Breath Res. 9(3), 031001 (2015).
  MedlineGoogle Scholar
• 105 He J, Sinues Martinez-Lozano P, Hollmén M, Li X, Detmar M, Zenobi R. Fingerprinting breast cancer vs. normal mammary cells by mass spectrometric analysis of volatiles. Sci. Rep. 4, 5196 (2014).
  Medline CASGoogle Scholar
• 106 Miekisch W, Herbig J, Schubert JK. Data interpretation in breath biomarker research: pitfalls and directions. J. Breath. Res. 6(3), 036007 (2012).
  MedlineGoogle Scholar
• 107 Righettoni M, Tricoli A, Pratsinis SE. Si:WO3 sensors for highly selective detection of acetone for easy diagnosis of diabetes by breath analysis. Anal. Chem. 82(9), 3581–3587 (2010).
  Medline CASGoogle Scholar
• 108 Sinues Martinez-Lozano P, Zenobi R, Kohler M. Analysis of the exhalome: a diagnostic tool of the future. Chest 144(3), 746–749 (2013).
  MedlineGoogle Scholar
• 109 Henry NL, Hayes DF. Cancer biomarkers. Mol. Oncol. 6(2), 140–146 (2012).
  Medline CASGoogle Scholar
• 110 Sestini S, Boeri M, Marchiano A et al. Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening. Oncotarget 6(32), 32868–32877 (2015).
  MedlineGoogle Scholar
• 111 Grenabo, Bergdahl A, Wilderäng U et al. Role of magnetic resonance imaging in prostate cancer screening: a pilot study within the Göteborg randomised screening trial. Eur. Urol. doi:10.1016/j.eururo.2015.12.006 (2015) (Epub ahead of print).
  Google Scholar